SecBot SecBot
SECBOTREPLAY Home › Report › VIR

VIR · Q3 loss narrows, Gilead deal

Vir Biotechnology, Inc. · 8-K filed Nov 4, 2026 at 16:10 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Nov 4, 2026 at 16:10 ET

Vir Biotechnology reported Q3 2026 net loss of $96.3M ($0.57 per share), narrower than the $163.1M loss in Q3 2025, driven by a $75M non-recurring milestone expense in the prior year. The company ended the quarter with $901.3M in cash and investments, entered a Gilead collaboration for up to $1.74B in milestones, and expects topline Phase 3 ECLIPSE 1 data in Q4 2026.

  • Q3 2026 net loss of $96.3M ($0.57 per share) vs $163.1M ($1.17 per share) in Q3 2025
  • Cash, cash equivalents and investments of $901.3M as of September 30, 2026, a decrease of $106.5M during Q3
  • Entered collaboration with Gilead for three PRO-XTEN dual-masked TCE candidates; received $90M upfront including $25M equity investment at 30% premium
  • VIR-5500 received FDA Fast Track designation and achieved proof of concept; pivotal trials expected to begin in 2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access